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Fabry disease is an inborn error of glycosphingolipid catabolism, resulting from deficient activity of lysosomal a-
galactosidase A (a-Gal A). A rare alternative splicing that introduces a 57-nucleotide (nt) intronic sequence to the
a-Gal A transcript from intron 4 of the gene has been identified. In addition, a novel midintronic base substitution
that results in substantially increased alternative splicing has been identified in a patient with Fabry disease who
has the cardiac variant phenotype. The sequence of the patient’s intron 4 contains a single GrA transversion at
genomic nt 9331 (IVS4+919GrA), located at the54 position of the 3′ end of the intronic insertion (nts 9278–9334
in the genomic sequence). Minigene constructs containing the entire intron 4 sequence with G, A, C, or T at nt
9331 within an a-Gal A complementary DNA expression vector were prepared and expressed in COS-1 cells.
Whereas transfection of the G or T minigenes transcribed predominantly normal-sized transcripts, the transfection
of the A or C minigenes produced a large amount of the alternatively spliced transcript. These results suggest that
the GrA mutation, within an A/C-rich domain, results in increased recognition of the alternative splicing by an
A/C-rich enhancer–type exonic splicing enhancer. The intronic mutation was not observed in 100 unrelated un-
affected men but was present in 6 unrelated patients with cardiac Fabry disease. Reverse-transcriptase polymerase
chain reaction of total RNA of various normal human tissues revealed that the alternatively spliced transcript was
present in all of the samples, and especially at a higher ratio in the lung and muscle. The normal transcript was
present in the patients’ lymphoblasts and resulted in ∼10% residual enzyme activity, leading to a cardiac phenotype
of Fabry disease.
Fabry disease (MIM 301500) is an X-linked recessive
inborn error of glycosphingolipid catabolism, caused by
lysosomal a-galactosidase A (a-Gal A, or GLA; Enzyme
Commission [EC] number 3.2.1.22) deficiency. The en-
zymatic defect results in the accumulation of neutral gly-
cosphingolipids with terminal a-galactosyl residues—
predominantly globotriaosylceramide—in body fluids
and in tissue lysosomes (Desnick et al. 2001). Classically
affected men with no a-Gal A activity have angiokera-
toma, acroparesthesias, hypohidrosis, and characteristic
corneal and lenticular opacities. In contrast, those af-
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flicted with a milder form have residual a-Gal A activity
and do not have the classical manifestations but typically
present with left-ventricular hypertrophy (Nakao et al.
1995) and have late-onset cardiomyopathy (Elleder et
al. 1990; Ogawa et al. 1990; von Scheidt et al. 1991).
To date, 1190 a-Gal A mutations that cause Fabry
disease have been described (HumanGeneMutationDa-
tabase Web site), and all of these mutations are located
within the coding or the flanking intronic sequences.
Mutations that cause the classic phenotype include mis-
sense and nonsense mutations, large and small insertions
or deletions, and splicing defects (Desnick et al. 2001).
In contrast, mutations that cause cardiac Fabry disease
include missense mutations, a small in-frame deletion,
and decreased a-Gal A mRNA (Desnick et al. 2001).
Among the mutations reported, all of the splicing mu-
tations have been found in the flanking regions of exons,
resulting in exon skipping or in misreading of the splice
site (Yokoi et al. 1991; Sakuraba et al. 1992; Eng et al.
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Figure 1 Identification of the mutant a-Gal A cDNA. A, To determine the sequence of the cDNA at the junction between exons 4 and
5, RT-PCR amplification of 0.1 mg of total RNA, prepared from the patient’s lymphoblasts and from normal lymphoblasts, was performed
using primers 5′-GTCCTTGGCCCTGAATAG-3′ and 5′-GTCCAGCAACATCAACAATT-3′, and the results were analyzed by agarose gel elec-
trophoresis. Lane 1, patient lymphoblasts; lane 2, normal lymphoblasts. B, To analyze the sequence of mutant a-Gal A cDNA, the RT-PCR
product amplified with the above primers was subcloned into the TA cloning pCR vector (Invitrogen), and the mutant cDNA fragment was
sequenced by an automated sequencer.
1993, 1997; Germain and Poenaru 1996, 1999; Oku-
miya et al. 1996; Matsumura et al. 1998; Topaloglu et
al. 1999).
During the course of mutant analysis of a patient with
cardiac Fabry disease (proband 1) who had residual en-
zyme activity of 8.7 U/mg protein (9.1% of normal) in
lymphoblasts, we were unable to identify any mutation
in the exonic or flanking intronic regions of the a-Gal
A gene. Therefore, we directed our efforts toward the
determination of the responsible mutation, by means of
RT-PCR of the RNA from the cardiac variant. Direct
sequencing of the RT-PCR product revealed an insertion
between exons 4 and 5 (data not shown). To further
characterize the abnormal splicing, RT-PCR of the re-
gion that includes exons 4 and 5 was performed. Two
bands were visualized on gel electrophoresis: the ex-
pected wild-type 215-bp fragment and a larger fragment,
∼270 base pairs in length (fig. 1A). This abnormal DNA
fragment was also found in the normal cells, at a very
low level. From the intensity of the DNA bands, it was
estimated that the abnormal a-Gal A mRNA in the pa-
tient’s lymphoblasts was 70% of the total a-Gal A
mRNA, whereas it was !5% of the total in normal lym-
phoblasts. These results suggested that the abnormal
DNA fragment was generated by a rare splicing event
within the a-Gal A gene.
To determine the sequence of the abnormal fragment,
the RT-PCR product generated from the patient’s lym-
phoblast RNA through use of primer set 5′-GTCCTTG-
GCCCTGAATAG-3′ and 5′-GTCCAGCAACATCAAC-
AATT-3′, which amplified a fragment that included
exons 4 and 5, was subcloned into the TA cloning pCR
vector (Invitrogen). Sequencing of the RT-PCR product
revealed a 57-nucleotide (nt) insertion at the junction
between exons 4 and 5 of the a-Gal A cDNA (fig. 1B),
consistent with the observed size of the RT-PCR product
from the patient’s lymphoblasts (fig. 1A). This insertion
corresponded to an intronic sequence in the gene at nts
9278–9334, which is located in the middle of intron 4.
This in-frame insertion caused a premature termination
at the 27th nucleotide downstream from exon 4. There-
fore, the predicted product of the mutant a-Gal A
mRNA was a truncated protein of 222 amino acid res-
idues. To examine whether the truncated protein exhib-
ited enzyme activity, an expression construct (pBaIns57)
containing the mutant insertion between exons 4 and 5
was prepared and expressed in COS-1 cells. A truncated
protein of 30 kD was detected by western blot analysis
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Figure 2 Transient expression of mutant a-Gal A cDNA inCOS-
1 cells. COS-1 cells were transfected with 1 mg of plasmid DNA and
8 ml of LipofectAMINE Reagent (Life Technologies). A, Western blot
analysis was performed using a rabbit anti-human a-Gal A antibody,
as described elsewhere (Ishii et al. 1994). Lane 1, mock transfection
(pBactE vector; see Koide et al. 1990); lane 2, pBaIns57, an a-Gal A
cDNA containing the 57-nt intronic insertion; lane 3, pBaN, a wild-
type a-Gal A expression construct (Ishii et al. 1992). Approximately
50 mg of protein was loaded in each well for SDS-PAGE analysis. The
truncated protein is indicated by an arrow. B, a-Gal A activity was
assayed with 4-methylumbelliferyl a-D-galactoside, as described by
Fan et al. (1999). Bars 1, 2, and 3 in the graph correspond to lanes
1, 2, and 3, respectively, in panel A. The enzyme activity is expressed
as the meanSD of triplicate experiments.
(fig. 2A). The enzyme activities in the mock-transfected
COS-1 cells and COS-1 cells transfected with pBaIns57
were 1533 U/mg and 1473 U/mg, respectively, com-
pared with 2,670200 U/mg in cells transfected with
the wild-type a-Gal A cDNA (pBaN; fig. 2B). These
results indicated that the C-terminal truncated protein
had no enzyme activity.
To determine the ratio of mutant and total (both
mutant and normal) a-Gal A mRNA in the patient’s
lymphoblasts, a quantitative competitive RT-PCR was
performed. DNA competitors were prepared by PCR
amplification of a l-DNA provided by the Competi-
tive DNA Construction Kit (Takara Shuzo), through
use of sense and antisense primers 5′-GCTCCACACT-
ATTTGGAAGTACGGTCATCATCTGACAC-3′ and
5′-AAAGGAGCAGCCATGATAGAACTATCGACA-
TCATTACGC-3′, for specific determination of the
mutant a-Gal A mRNA, or sense and antisense prim-
ers 5′-GGTTGGAATGACCCAGATAGTACGGTCA-
TCATCTGACAC-3′ and 5′-TGCGATGGTATAAGA-
GCGCAGTTAATCGAACAAGAC-3′, for specific de-
termination of total a-Gal A mRNA. A 298-bp PCR
product or a 324-bp PCR product was amplified in
the presence of the respective competitors to detect
either mutant a-Gal A mRNA or both normal and
mutant a-Gal A mRNAs, respectively (fig. 3A). The
total a-Gal A mRNA amount was essentially the same
in both the normal cells and the patient’s cells (fig.
3B). On the other hand, the 298-bp mutant fragment
was the predominant product in the patient’s cells,
whereas this fragment was present at a very low level
in the normal cells (fig. 3C). On the basis of the in-
tensity of the DNA bands, the mutant a-Gal A mRNA
was estimated to be present at ∼115 copies, compared
with the DNA competitor; this amount was ∼10-fold
higher than that in the normal cells (10 copies) (fig.
3D).
To determine whether the alternative splicing occurred
in human tissues, RT-PCR between exons 4 and 5 was
performed using total tissue RNA (fig. 4). The alterna-
tively spliced transcript (the 272-bp fragment) was ob-
served in a trace amount (!1% of total a-Gal A mRNA)
in heart and small intestine, and a small amount (!10%)
was observed in kidney, spleen, and liver. However, the
ratio of the abnormal transcript to the total a-Gal A
mRNA was higher in muscle and lung. These results
clearly indicate that this abnormal transcript is indeed
an alternative splicing product of the human a-Gal A
gene.
Intron 4 (nts 8413–10130) of the a-Gal A gene was
sequenced using genomic DNA prepared from the pa-
tient’s lymphoblasts. Four differences were observed
when it was compared with the sequence reported by
Kornreich et al. (1989): a GrA transition was present
at nt 9331, an ArG transition was present at nt 9401,
a G insertion was present at nt 9828, and a CGrGC
transversion was present at nt 9876. Because the sub-
stitution at nt 9401, the insertion at nt 9828, and the
transversions at nt 9876 were detected in genomic DNA
of an unaffected Japanese male (data not shown), only
the GrA transition at nt 9331 (IVS4919GrA) was
considered to be patient-specific. To determine whether
the GrA transition at nt 9331 was a polymorphism,
genomic DNA from 100 unaffected Japanese males was
amplified and analyzed for the GrA substitution by BfaI
digestion, since the GrA transversion at nt 9331 dis-
rupts a BfaI cleavage site. All of the PCR products were
completely cleaved by the enzyme (data not shown), in-
dicating that this transversion was not present in 100
normal alleles.
The 57-nt sequence inserted in the mutant a-Gal A
mRNA was identical to the genomic sequence at nts
9278–9334 in the patient (fig. 5A). The invariant GT
and AG dinucleotides involved in the splicing were pres-
ent at both sites of the 57-nt sequence, and a 10-nt
polypyrimidine tract (nts 9265–9275) was observed up-
stream of the 3′ AG acceptor site. It is known that ef-
ficient splicing of mammalian RNAs involves four se-
quence elements in introns: (1) a conserved GT dinu-
cleotide at the 5′ splice junction, (2) an invariant AG
dinucleotide at the 3′ splice junction, (3) a weakly con-
served sequence at the site of lariat formation with an
adenine at the branch point, and (4) a pyrimidine-rich
region of variable length between the branch point and
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Figure 3 Quantitative analysis of the mutant a-Gal A mRNA. The relative amounts of normal andmutant a-Gal AmRNAwere determined
by a competitive RT-PCR method (Becker-Andre and Hahlbrock 1989). The concentration of total RNA prepared from the lymphoblasts was
determined by OD260 and was adjusted using the human b-actin Competitive PCR Set (Takara Shuzo). RT was performed with 0.6 mg of total
RNA in 60 ml of the reaction mixture, through use of the RNA PCR Kit (Takara Shuzo). Aliquots (5 ml) of the RT reaction were used for PCR
amplifications of mutant or total a-Gal A mRNAs. A, Diagram of mutant a-Gal A mRNA and the location of the primers. In the assay of
mutant a-Gal AmRNA, target (298 bp) and competitor (249 bp) DNA fragments were amplifiedwith primer set P1 (5′-GCTCCACACTATTTGG-
AAG-3′) and P2 (5′-AAAGGAGCAGCCATGATAG-3′) and DNA competitors prepared specifically for the mutant a-Gal A mRNA (see text)
at various concentrations. In the assay for the total a-Gal A mRNA, target (324 bp) and competitor (275 bp) DNA fragments were amplified
with primers P3 (5′-GGTTGGAATGACCCAGATA-3′) and P4 (5′-TGCGATGGTATAAGAGCG-3′) and DNA competitors prepared specifically
for the total a-Gal A mRNA (both mutant and normal) at various concentrations. The relative amounts of the total a-Gal A mRNA (B) and
the mutant a-Gal A mRNA (C) in both the patient’s lymphoblasts and the normal lymphoblasts were determined by comparison with the
competitors’ concentration, indicated at the top of the photos. D, After agarose gel electrophoresis, the concentrations of the PCR products
were determined using an image processing system, according the method reported elsewhere (Minamikawa-Tachino et al. 1993). Circles p
patient; triangles p unaffected subject; Ex p exon; T p target; C p competitor.
the 3′ splice junction, referred to as the polypyrimidine
tract (Padgett et al. 1986; Shapiro and Senapathy 1987).
All of the structural characters surrounding the insertion
site indicate that the 57-nt sequence could be an addi-
tional exon in the a-Gal A gene. Studies (Dominski and
Kole 1991) on the effects that internal exon length has
on splice-site selection have revealed that internal exons
187 nts in length were included in the splice product,
whereas complete skipping of an internal exon was ob-
served when the exons were !33 nt in length. A 51-nt
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Figure 4 Alternative splicing in human tissues. RT-PCR was
performed with 0.1 mg of total human tissue RNA obtained from
OriGene, as described in the legend to figure 1. Lane 1, heart; lane 2,
kidney; lane 3, spleen; lane 4, liver; lane 5, small intestine; lane 6,
muscle; lane 7, lung; lane 8, lymphoblasts.
exon was processed in vitro to result in both skipped
products and included products, and the importance of
these elements has been shown experimentally in studies
employing pre-mRNAs that contain point mutations or
deletions within an existing sequence (Aebi et al. 1986).
In the present case, a slightly shorter sequence, generated
by deletion of 3 bp from the 57-nt sequence, was ex-
clusively skipped from the transcript (data not shown),
suggesting that the length of 57-nt probably limits the
inclusion of this sequence. This may be the reason that
only low-level splicing of this intronic sequence (∼5%
of a-Gal A mRNA) occurred in normal lymphoblasts
and tissues.
To evaluate whether the GrA transition at nt 9331
was responsible for the mutant a-Gal A mRNA in the
patient’s cells, minigene constructs containing the entire
normal intron 4 sequence (pCXN2Gal/int4N) or the pa-
tient’s intron 4 sequence (pCXN2Gal/int4P) were pre-
pared and then expressed in COS-1 cells. To confirm
that the pCXN2Gal/int4P construct contained the GrA
transition, the minigene construct was digested with
BfaI. Presence of a 427-bp fragment (nts 9116–9543)
after the enzyme digestion indicated the presence of the
mutation in pCXN2Gal/int4P (data not shown), since
this fragment would be cleaved into two smaller frag-
ments by the enzyme if the wild-type sequence was pre-
sent. a-Gal A activity in COS-1 cells transfected with
both normal and mutant constructs was detected, al-
though the enzyme activity was substantially lower in
the cells transfected with pCXN2Gal/int4P, suggesting
that the minigene constructs were transcribed, spliced,
and translated in the COS-1 cells. a-Gal A mRNA was
analyzed by RT-PCR of total RNA isolated from the
transfected COS-1 cells. A large amount of the 272-bp
RT-PCR fragment was obtained from the COS-1 cells
transfected with pCXN2Gal/int4P, indicating that al-
ternative splicing of the a-Gal A transcript occurred
in COS-1 cells (fig. 5B). This indicated that the
IVS4919GrA mutation is responsible for the drastic
increase of the alternative splicing in intron 4.
Intronic mutations have been found to cause many
human diseases, including b-thalassemia (Treisman et al.
1983), ornithine d-aminotransferase deficiency (Mitchell
et al. 1991), and ataxia-telangiectasia (Teraoka et al.
1999). These mutations often exist in consensus AG/GT
dinucleotides, the branch point, or the polypyrimidine
tract of a cryptic exon, resulting in inclusion of the cryp-
tic exon or in changing of the normal splicing site up-
stream of the cryptic exon. In the present case, the
IVS4919GrA mutation that drastically changes the
splicing of the 57-nt sequence is located within the al-
ternative splicing exon. To assess the mechanism of the
alternative splicing, additional minigeneswithmutations
at the 4 position and its surrounding region were gen-
erated by site-directed mutagenesis, and COS-1 cells
were transfected with minigenes of a-Gal A cDNA
containing intron 4 with IVS4919GrC (pCXN2Gal/
int4C) or IVS4919GrT (pCXN2Gal/int4T) transver-
sions. Only the IVS4919GrC transversion, and not
the GrT transversion, was shown to increase the inclu-
sion of the 57-nt sequence (fig. 5B), indicating that an
A or C at the position activates the alternative splicing.
Exonic splicing enhancers (ESEs) that direct the spe-
cific recognition of splicing sites during constitutive and
alternative splicing are found within both coding and
noncoding exons (Blencowe 2000). The most common
feature of ESEs is that most are purine rich (Eldridge et
al. 1999). Sequences other than purine-rich repeats have
also been characterized as exon enhancers. For example,
novel A/C-rich enhancers (ACEs) have been identified
both in natural genes and in experiments designed to
select exon enhancers. The ACEs were reported from
human calcitonin exon 4 (van Oers et al. 1994), chicken
cTNT exon 16 (Wang et al. 1995), and Drosophila
doublesex exon 4 (Ryner and Baker 1991; Lynch and
Maniatis 1995). Disruption of an ESE in the coding se-
quence can cause inappropriate exon skipping in vitro
(Liu et al. 2001). In the 57-nt sequence, an A/C-rich
sequence (nts 9323–9332: CCCCACUAGA) was ob-
served in the alternative splicing exon within intron 4
of the a-Gal A gene. The IVS4919GrA/C substitu-
tions could further enrich the A/C predominance for the
sequence and, thus, could increase the recognition of the
alternative splice site. Therefore, the ACE recognition
mechanism may be involved in the alternative splicing
of the a-Gal A gene. ACE-type ESEs are not as common
as purine-rich–type ESEs. Recently, the RNA-binding
protein YB-1 was reported to bind ACEs and to stim-
ulate the alternative splicing of the CD44 exon v4 (Stick-
eler et al. 2001), although the detailed structural mech-
anism was not revealed. Our finding of the increased
alternative splicing in a-Gal A gene could be valu-
able for the elucidation of the mechanism of the ACE
enhancement.
Mutations in another patient with Fabry disease (pro-
band 2) with the cardiac variant and in four patients
with Fabry disease of the cardiac phenotype (or atypical
Fabry disease) previously characterized as expressing a
decreased level of a-Gal A mRNA (Nakao et al. 1995)
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Figure 5 Contribution of nucleotide at nt 9331 to alternative splicing. A, Sequence of a-Gal A intron 4 from the patient. The 57-nt
sequence is enclosed in the box. The GrA transition at nt 9331 is indicated by an arrow. The polypyrimidine tract is indicated by double
underlining. B, Transient expression of minigene constructs in COS-1 cells. Minigene constructs containing the entire normal or mutant intron
4 were prepared as follows: fragment A (nts 8324–9450) was amplified, from genomic DNA of an unaffected subject, with primers 5′-
ATAAGCACATGTCCTTGGC-3′ and 5′-TGCAGAGATAATGAGGGAAT-3′ and then was digested with AflIII and SacI; fragment B (nts
9112–10282) was amplified from normal or mutant genomic DNAwith primers 5′-CTGCCTAGAACAGTTCTTC-3′ and5′-TCATTCCAACCC-
CCTGGT-3′, followed by digestion with SacI and BstXI. The 951-bp AflIII-SacI–digested fragment A was ligated to the 992-bp SacI-
BstXI–digested fragment B, to generate a 1,943-bp AflIII-BstXI fragment that was inserted into the AflIII-BstXI of the pCXN2Gal expression
construct (Ishii et al. 1993). The constructs containing normal and patient intron 4 were designated as “pCXN2Gal/Int4N” and “pCXN2Gal/
Int4P,” respectively. To generate the GrC and GrT conversions at the nt 9331 mutation site, site-directed mutagenesis by Pfu-polymerase–based
PCR using the QuickChange kit (Stratagene) was performed in a small fragment (SacI-XmaI, nts 9282–9587) of a-Gal A intron 4. The complete
sequence of the mutated fragment was confirmed by DNA sequencing. The fragment with the desired mutation was subcloned into its original
position in a minigene construct using two steps of subcloning. First it was inserted into a vector containing NheI-XmaI (exons 2–4 [nts 358–639
of cDNA] and intron 4 [nts 8413–9587 of genomic DNA]). Next, it was transferred to the pCXN2 expression vector that contains the full-
length a-Gal A cDNA and intron 4. The constructs containing the GrC or GrT conversion are designated “pCXN2Gal/Int4C” or “pCXN2Gal/
Int4T,” respectively. COS-1 cells transfected with 1 mg of plasmid DNA were grown for 2 d, and RT-PCR analysis was performed using primer
pair 5′-GTCCTTGGCCCTGAATAG-3′ and 5′-GTCCAGCAACATCAACAATT-3′ and total RNA prepared from COS-1 cells transfected with
each plasmid construct. Lane 1, mock transfection, pCXN2 vector (Niwa et al. 1991); lane 2, pCXN2Gal/Int4N; lane 3, pCXN2Gal/Int4P;
lane 4, pCXN2Gal/Int4T; lane 5, pCXN2Gal/Int4C.
were analyzed in the present study. Proband 2 had re-
sidual lymphoblast a-Gal A activity that was 10.6% of
normal. The residual enzyme activities in other patients
were 8%–15% of normal. BfaI digestion of the genomic
fragment containing the substitution site did not cleave
the fragment from these patients (fig. 6A), clearly indi-
cating the presence of the GrA substitution. These re-
sults were confirmed by sequencing of the appropriate
PCR products (data not shown). RT-PCR amplification
of total RNA from these patients’ lymphoblasts revealed
a high level of mutant a-Gal A mRNA, detected as a
272-bp fragment (fig. 6B). The percentage of mutant a-
Gal A mRNAwas 64%–88%. In contrast, only 5%–8%
of the alternatively spliced mRNA was detected in the
lymphoblasts from unaffected subjects or from patients
with Fabry disease who had missense mutations. These
results indicated that the increased alternative splicing
in these patients with cardiac Fabry disease was caused
by the GrA substitution at nt 9331 and that the deficient
enzyme activity was due to a decreased level of normal
a-Gal A transcript. Accordingly, these patients should
appropriately be classified as having the alternative splic-
ing mutations.
The cardiac variant of Fabry disease is usually asso-
ciated with residual a-Gal A activity at 5%–10% of
normal level. The residual enzyme activities in the pa-
tients with cardiac Fabry disease in the present study
were determined to be ∼10% of normal. On the basis
of RT-PCR amplification, the amount of mutant a-Gal
A mRNA in the patients’ lymphoblasts was 64%–88%
of the total a-Gal A mRNA, and the product of the
mutant a-Gal A mRNA was a truncated polypeptide of
222 amino acid residues that had no detectable enzy-
matic activity (fig. 2B). The remainder of the normal a-
Gal A mRNA was transcribed to result in the 10% re-
sidual a-Gal A activity and cause the cardiac variant
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Figure 6 Detection of the mutation in unrelated patients with
cardiac Fabry disease. The mutation can be readily detected by re-
striction enzyme analysis, because the GrA transition at nt 9331 dis-
rupts a BfaI cleavage site. The mutant 334-bp fragment was not di-
gested, whereas the normal fragment was cleaved into fragments of
212 bp and 122 bp. A, PCR fragment (334 bp; nts 9117–9450) am-
plified from genomic DNA with primers 5′-TAGAACAGTTCTTCCC-
CAA-3′ and 5′-TGCAGAGATAATGAGGGAAT-3′, digested with BfaI
(New England Biolabs) and analyzed by agarose gel electrophoresis.
B, RT-PCR analyses performed as described in the legend to figure 1,
through use of total RNA from normal lymphoblasts or patient lym-
phoblasts. Lane 1, unaffected; lanes 2 and 3, probands 1 and 2; lanes
4, 5, 6, and 7, patients 2, 3, 6, and 7, respectively, all with Fabry
disease and reported previously as having decreased a-Gal A mRNA
content (Nakao et al. 1995); lane 8, patient with Fabry disease who
has the M296I mutation (Nakao et al. 1995); lane 9, patient with
Fabry disease who has the R301Q mutation (Sakuraba et al. 1990).
phenotype. The truncated a-Gal A polypeptide may be
also translated from the small amount of the abnormal
a-Gal A mRNA in normal cells. However, it may be
rapidly degraded in situ, since we were unable to detect
the truncated protein in the patient’s lymphoblasts, al-
though it was barely detected in COS-1 cells transfected
with pBaIns57 (fig. 3A). Combining six unrelated pa-
tients who had cardiac Fabry disease retained the same
mutation; this mutation may be considered to be a major
mutation in Fabry disease, particularly in the patients
who have no mutation in the coding and flanking
regions. Until now, all splicing mutations reported in
Fabry disease have been nucleotide substitutions or a
single base deletion at or near the invariant dinucleotides
of an intron, resulting in exon skipping or misreading
of the splicing site (Yokoi et al. 1991; Sakuraba et al.
1992; Eng et al. 1993, 1997; Germain and Poenaru
1996, 1999; Okumiya et al. 1996; Matsumura et al.
1998; Topaloglu et al. 1999). The IVS4919GrA mu-
tation was unique because it occurred in the middle of
an intron, and it increased the recognition of a normally
weak splice site, resulting in the insertion of an addi-
tional sequence into the a-Gal A transcript, which leads
to the cardiac phenotype of Fabry disease.
In summary, we report for the first time that there is
a normally weakly regulated alternative splice site in the
human a-Gal A gene. In addition, we determined that
a novel intronic mutation causes a remarkable increase
in the alternatively spliced a-Gal A transcript and, con-
sequently, results in the cardiac phenotype of Fabry
disease.
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